Mycophenolate mofetil in the treatment of pediatric autoimmune central nervous system disease.
Publication
, Journal Article
Stingl, C; Van Mater, H
Published in: Dev Med Child Neurol
April 2019
Duke Scholars
Published In
Dev Med Child Neurol
DOI
EISSN
1469-8749
Publication Date
April 2019
Volume
61
Issue
4
Start / End Page
388
Location
England
Related Subject Headings
- Pediatrics
- Mycophenolic Acid
- Immunosuppressive Agents
- Humans
- Child
- Central Nervous System Diseases
- Autoimmune Diseases
- 52 Psychology
- 42 Health sciences
- 32 Biomedical and clinical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Stingl, C., & Van Mater, H. (2019). Mycophenolate mofetil in the treatment of pediatric autoimmune central nervous system disease. Dev Med Child Neurol, 61(4), 388. https://doi.org/10.1111/dmcn.14098
Stingl, Cory, and Heather Van Mater. “Mycophenolate mofetil in the treatment of pediatric autoimmune central nervous system disease.” Dev Med Child Neurol 61, no. 4 (April 2019): 388. https://doi.org/10.1111/dmcn.14098.
Stingl C, Van Mater H. Mycophenolate mofetil in the treatment of pediatric autoimmune central nervous system disease. Dev Med Child Neurol. 2019 Apr;61(4):388.
Stingl, Cory, and Heather Van Mater. “Mycophenolate mofetil in the treatment of pediatric autoimmune central nervous system disease.” Dev Med Child Neurol, vol. 61, no. 4, Apr. 2019, p. 388. Pubmed, doi:10.1111/dmcn.14098.
Stingl C, Van Mater H. Mycophenolate mofetil in the treatment of pediatric autoimmune central nervous system disease. Dev Med Child Neurol. 2019 Apr;61(4):388.
Published In
Dev Med Child Neurol
DOI
EISSN
1469-8749
Publication Date
April 2019
Volume
61
Issue
4
Start / End Page
388
Location
England
Related Subject Headings
- Pediatrics
- Mycophenolic Acid
- Immunosuppressive Agents
- Humans
- Child
- Central Nervous System Diseases
- Autoimmune Diseases
- 52 Psychology
- 42 Health sciences
- 32 Biomedical and clinical sciences